Trial
NCT00052598
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Accelerated Phase Chronic Myelogenous Leukemia
Intervention
therapeutic allogeneic lymphocytes
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-15